Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Clin Genet ; 103(6): 699-703, 2023 06.
Article in English | MEDLINE | ID: mdl-36807241

ABSTRACT

Hereditary deafness and retinal dystrophy are each genetically heterogenous and clinically variable. Three small unrelated families segregating the combination of deafness and retinal dystrophy were studied by exome sequencing (ES). The proband of Family 1 was found to be compound heterozygous for NM_004525.3: LRP2: c.5005A > G, p.(Asn1669Asp) and c.149C > G, p.(Thr50Ser). In Family 2, two sisters were found to be compound heterozygous for LRP2 variants, p.(Tyr3933Cys) and an experimentally confirmed c.7715 + 3A > T consensus splice-altering variant. In Family 3, the proband is compound heterozygous for a consensus donor splice site variant LRP2: c.8452_8452 + 1del and p.(Cys3150Tyr). In mouse cochlea, Lrp2 is expressed abundantly in the stria vascularis marginal cells demonstrated by smFISH, single-cell and single-nucleus RNAseq, suggesting that a deficiency of LRP2 may compromise the endocochlear potential, which is required for hearing. LRP2 variants have been associated with Donnai-Barrow syndrome and other multisystem pleiotropic phenotypes different from the phenotypes of the four cases reported herein. Our data expand the phenotypic spectrum associated with pathogenic variants in LRP2 warranting their consideration in individuals with a combination of hereditary hearing loss and retinal dystrophy.


Subject(s)
Deafness , Hearing Loss, Sensorineural , Hearing Loss , Myopia , Retinal Dystrophies , Animals , Mice , Humans , Hearing Loss, Sensorineural/genetics , Deafness/genetics , Myopia/genetics , Mutation , Pedigree , Low Density Lipoprotein Receptor-Related Protein-2/genetics
2.
Clin Genet ; 99(2): 226-235, 2021 02.
Article in English | MEDLINE | ID: mdl-33089500

ABSTRACT

Usher syndrome has been historically categorized into one of three classical types based on the patient phenotype. However, the vestibular phenotype does not infallibly predict which Usher genes are mutated. Conversely, the Usher syndrome genotype is not sufficient to reliably predict vestibular function. Here we present a characterization of the vestibular phenotype of 90 patients with clinical presentation of Usher syndrome (59 females), aged 10.9 to 75.5 years, with genetic variants in eight Usher syndromic genes and expand the description of atypical Usher syndrome. We identified unexpected horizontal semicircular canal reactivity in response to caloric and rotational stimuli in 12.5% (3 of 24) and 41.7% (10 of 24), respectively, of our USH1 cohort. These findings are not consistent with the classical phenotypic definition of vestibular areflexia in USH1. Similarly, 17% (6 of 35) of our cohort with USH2A mutations had saccular dysfunction as evidenced by absent cervical vestibular evoked myogenic potentials in contradiction to the classical assumption of normal vestibular function. The surprising lack of consistent genotypic to vestibular phenotypic findings as well as no clear vestibular phenotypic patterns among atypical USH cases, indicate that even rigorous vestibular phenotyping data will not reliably differentiate the three USH types.


Subject(s)
Usher Syndromes/genetics , Usher Syndromes/physiopathology , Vestibule, Labyrinth/physiopathology , Adolescent , Adult , Aged , Child , Cohort Studies , Energy Intake , Evoked Potentials, Auditory , Female , Genetic Association Studies , Humans , Middle Aged , Prospective Studies , Young Adult
3.
Br J Clin Pharmacol ; 84(2): 215-222, 2018 02.
Article in English | MEDLINE | ID: mdl-28925019

ABSTRACT

Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.


Subject(s)
Biomedical Research/methods , Breast Feeding , Clinical Trials as Topic/methods , Drug-Related Side Effects and Adverse Reactions/epidemiology , Pharmaceutical Preparations/administration & dosage , Pregnancy Complications/drug therapy , Biomedical Research/legislation & jurisprudence , Clinical Trials as Topic/legislation & jurisprudence , Female , Government Regulation , Guidelines as Topic , Humans , Pharmacoepidemiology , Pregnancy , United States , United States Food and Drug Administration
4.
Am J Obstet Gynecol ; 215(1 Suppl): S1-S46, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26972897

ABSTRACT

Although much progress is being made in understanding the molecular pathways in the placenta that are involved in the pathophysiology of pregnancy-related disorders, a significant gap exists in the utilization of this information for the development of new drug therapies to improve pregnancy outcome. On March 5-6, 2015, the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health sponsored a 2-day workshop titled Placental Origins of Adverse Pregnancy Outcomes: Potential Molecular Targets to begin to address this gap. Particular emphasis was given to the identification of important molecular pathways that could serve as drug targets and the advantages and disadvantages of targeting these particular pathways. This article is a summary of the proceedings of that workshop. A broad number of topics were covered that ranged from basic placental biology to clinical trials. This included research in the basic biology of placentation, such as trophoblast migration and spiral artery remodeling, and trophoblast sensing and response to infectious and noninfectious agents. Research findings in these areas will be critical for the formulation of the development of future treatments and the development of therapies for the prevention of a number of pregnancy disorders of placental origin that include preeclampsia, fetal growth restriction, and uterine inflammation. Research was also presented that summarized ongoing clinical efforts in the United States and in Europe that has tested novel interventions for preeclampsia and fetal growth restriction, including agents such as oral arginine supplementation, sildenafil, pravastatin, gene therapy with virally delivered vascular endothelial growth factor, and oxygen supplementation therapy. Strategies were also proposed to improve fetal growth by the enhancement of nutrient transport to the fetus by modulation of their placental transporters and the targeting of placental mitochondrial dysfunction and oxidative stress to improve placental health. The roles of microRNAs and placental-derived exosomes, as well as messenger RNAs, were also discussed in the context of their use for diagnostics and as drug targets. The workshop discussed the aspect of safety and pharmacokinetic profiles of potential existing and new therapeutics that will need to be determined, especially in the context of the unique pharmacokinetic properties of pregnancy and the hurdles and pitfalls of the translation of research findings into practice. The workshop also discussed novel methods of drug delivery and targeting during pregnancy with the use of macromolecular carriers, such as nanoparticles and biopolymers, to minimize placental drug transfer and hence fetal drug exposure. In closing, a major theme that developed from the workshop was that the scientific community must change their thinking of the pregnant woman and her fetus as a vulnerable patient population for which drug development should be avoided, but rather be thought of as a deprived population in need of more effective therapeutic interventions.


Subject(s)
Molecular Targeted Therapy , Placenta Diseases/drug therapy , Placenta , Animals , Biomarkers/metabolism , Drug Delivery Systems , Drug Discovery , Female , Genetic Markers , Humans , Mice , Models, Animal , National Institute of Child Health and Human Development (U.S.) , Placenta/embryology , Placenta/immunology , Placenta/metabolism , Placenta/physiopathology , Placenta Diseases/genetics , Placenta Diseases/metabolism , Placenta Diseases/physiopathology , Pregnancy , Pregnancy Outcome , Rats , Translational Research, Biomedical , United States
5.
Ophthalmology ; 120(7): 1324-36, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23601806

ABSTRACT

OBJECTIVE: Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by mutations in DNA repair genes. Clinical manifestations of XP include mild to extreme sensitivity to ultraviolet radiation resulting in inflammation and neoplasia in sun-exposed areas of the skin, mucous membranes, and ocular surfaces. This report describes the ocular manifestations of XP in patients systematically evaluated in the Clinical Center at the National Institutes of Health. DESIGN: Retrospective observational case series. PARTICIPANTS: Eighty-seven participants, aged 1.3 to 63.4 years, referred to the National Eye Institute (NEI) for examination from 1964 to 2011. Eighty-three patients had XP, 3 patients had XP/Cockayne syndrome complex, and 1 patient had XP/trichothiodystrophy complex. METHODS: Complete age- and developmental stage-appropriate ophthalmic examination. MAIN OUTCOME MEASURES: Visual acuity; eyelid, ocular surface, and lens pathology; tear film and tear production measures; and cytologic analysis of conjunctival surface swabs. RESULTS: Of the 87 patients, 91% had at least 1 ocular abnormality. The most common abnormalities were conjunctivitis (51%), corneal neovascularization (44%), dry eye (38%), corneal scarring (26%), ectropion (25%), blepharitis (23%), conjunctival melanosis (20%), and cataracts (14%). Thirteen percent of patients had some degree of visual axis impingement, and 5% of patients had no light perception in 1 or both eyes. Ocular surface cancer or a history of ocular surface cancer was present in 10% of patients. Patients with an acute sunburning skin phenotype were less likely to develop conjunctival melanosis and ectropion but more likely to develop neoplastic ocular surface lesions than nonburning patients. Some patients also showed signs of limbal stem cell deficiency. CONCLUSIONS: Our longitudinal study reports the ocular status of the largest group of patients with XP systematically examined at 1 facility over an extended period of time. Structural eyelid abnormalities, neoplasms of the ocular surface and eyelids, tear film and tear production abnormalities, ocular surface disease and inflammation, and corneal abnormalities were present in this population. Burning and nonburning patients with XP exhibit different rates of important ophthalmologic findings, including neoplasia. In addition, ophthalmic characteristics can help refine diagnoses in the case of XP complex phenotypes. DNA repair plays a major role in protection of the eye from sunlight-induced damage.


Subject(s)
DNA Repair/physiology , DNA/radiation effects , Eye Diseases/diagnosis , Radiation Injuries/diagnosis , Sunlight/adverse effects , Xeroderma Pigmentosum/diagnosis , Adolescent , Adult , Child , Child, Preschool , Cockayne Syndrome/diagnosis , Cockayne Syndrome/etiology , Cockayne Syndrome/prevention & control , Eye Diseases/etiology , Eye Diseases/prevention & control , Female , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Radiation Injuries/etiology , Radiation Injuries/prevention & control , Retrospective Studies , Trichothiodystrophy Syndromes/diagnosis , Trichothiodystrophy Syndromes/etiology , Trichothiodystrophy Syndromes/prevention & control , Ultraviolet Rays/adverse effects , Visual Acuity/physiology , Xeroderma Pigmentosum/etiology , Xeroderma Pigmentosum/prevention & control , Young Adult
6.
J Med Genet ; 48(11): 767-75, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21940737

ABSTRACT

BACKGROUND: Recessive mutant alleles of MYO7A, USH1C, CDH23, and PCDH15 cause non-syndromic deafness or type 1 Usher syndrome (USH1) characterised by deafness, vestibular areflexia, and vision loss due to retinitis pigmentosa. For CDH23, encoding cadherin 23, non-syndromic DFNB12 deafness is associated primarily with missense mutations hypothesised to have residual function. In contrast, homozygous nonsense, frame shift, splice site, and some missense mutations of CDH23, all of which are presumably functional null alleles, cause USH1D. The phenotype of a CDH23 compound heterozygote for a DFNB12 allele in trans configuration to an USH1D allele is not known and cannot be predicted from current understanding of cadherin 23 function in the retina and vestibular labyrinth. METHODS AND RESULTS: To address this issue, this study sought CDH23 compound heterozygotes by sequencing this gene in USH1 probands, and families segregating USH1D or DFNB12. Five non-syndromic deaf individuals were identified with normal retinal and vestibular phenotypes that segregate compound heterozygous mutations of CDH23, where one mutation is a known or predicted USH1 allele. CONCLUSIONS: One DFNB12 allele in trans configuration to an USH1D allele of CDH23 preserves vision and balance in deaf individuals, indicating that the DFNB12 allele is phenotypically dominant to an USH1D allele. This finding has implications for genetic counselling and the development of therapies for retinitis pigmentosa in Usher syndrome. ACCESSION NUMBERS: The cDNA and protein Genbank accession numbers for CDH23 and cadherin 23 used in this paper are AY010111.2 and AAG27034.2, respectively.


Subject(s)
Cadherins/genetics , Hearing Loss, Sensorineural/genetics , Mutation , Retina/metabolism , Retinitis Pigmentosa/genetics , Usher Syndromes/genetics , Vestibule, Labyrinth/metabolism , Adolescent , Adult , Alleles , Asian People/genetics , Asymptomatic Diseases , Cadherin Related Proteins , Child , Cohort Studies , DNA Mutational Analysis , Exons , Female , Genetic Association Studies , Genotype , Hearing Loss, Sensorineural/pathology , Heterozygote , Humans , Male , Pedigree , Phenotype , Retina/pathology , Retinitis Pigmentosa/pathology , United States , Usher Syndromes/pathology , Vestibule, Labyrinth/pathology , White People/genetics
7.
J Invest Dermatol ; 131(12): 2394-400, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21833017

ABSTRACT

Hermansky-Pudlak syndrome (HPS) is an autosomal recessive condition characterized by a bleeding diathesis and hypopigmentation of the skin, hair, and eyes. Some HPS patients develop other complications such as granulomatous colitis and/or fatal pulmonary fibrosis. Eight genes have been associated with this condition, resulting in subtypes HPS-1 through HPS-8. The HPS gene products are involved in the biogenesis of specialized lysosome-related organelles such as melanosomes and platelet delta granules. HPS1 and HPS4 form a stable complex named biogenesis of lysosome-related organelles complex (BLOC)-3, and patients with BLOC-3 or AP-3 deficiency develop pulmonary fibrosis. Therefore, it is important to subtype each HPS patient. HPS type 1 (HPS-1) occurs frequently on the island of Puerto Rico because of a founder mutation. Here, we describe seven mutations, six of which, to our knowledge, are previously unreported in the HPS1, HPS4, and HPS5 genes among patients of Mexican, Uruguayan, Honduran, Cuban, Venezuelan, and Salvadoran ancestries. Our findings demonstrate that the diagnosis of HPS should be considered in Hispanic patients with oculocutaneous albinism and bleeding symptoms. Moreover, such patients should not be assumed to have the HPS-1 subtype typical of northwest Puerto Rican patients. We recommend molecular HPS subtyping in such cases, as it may have significant implications for prognosis and intervention.


Subject(s)
Carrier Proteins/genetics , Hermanski-Pudlak Syndrome/genetics , Hispanic or Latino/genetics , Membrane Proteins/genetics , Proteins/genetics , Adolescent , Adult , Albinism, Oculocutaneous/genetics , Base Sequence , Child, Preschool , Female , Guanine Nucleotide Exchange Factors , Hemorrhage/genetics , Humans , Infant , Male , Molecular Sequence Data , Mutation , Prognosis
8.
Mol Genet Metab ; 103(4): 307-14, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21620748

ABSTRACT

Alkaptonuria is a rare, autosomal recessive disorder of tyrosine degradation due to deficiency of the third enzyme in the catabolic pathway. As a result, homogentisic acid (HGA) accumulates and is excreted in gram quantities in the urine, which turns dark upon alkalization. The first symptoms, occurring in early adulthood, involve a painful, progressively debilitating arthritis of the spine and large joints. Cardiac valvular disease and renal and prostate stones occur later. Previously suggested therapies have failed to show benefit, and management remains symptomatic. Nitisinone, a potent inhibitor of the second enzyme in the tyrosine catabolic pathway, is considered a potential therapy; proof-of-principle studies showed 95% reduction in urinary HGA. Based on those findings, a prospective, randomized clinical trial was initiated in 2005 to evaluate 40 patients over a 36-month period. The primary outcome parameter was hip total range of motion with measures of musculoskeletal function serving as secondary parameters. Biochemically, this study consistently demonstrated 95% reduction of HGA in urine and plasma over the course of 3 years. Clinically, primary and secondary parameters did not prove benefit from the medication. Side effects were infrequent. This trial illustrates the remarkable tolerability of nitisinone, its biochemical efficacy, and the need to investigate its use in younger individuals prior to development of debilitating arthritis.


Subject(s)
4-Hydroxyphenylpyruvate Dioxygenase/antagonists & inhibitors , Alkaptonuria/drug therapy , Cyclohexanones/therapeutic use , Nitrobenzoates/therapeutic use , Adult , Alkaptonuria/blood , Alkaptonuria/urine , Homogentisic Acid/blood , Homogentisic Acid/urine , Humans , Middle Aged , Prospective Studies , Tyrosine/metabolism
10.
Adv Otorhinolaryngol ; 70: 56-65, 2011.
Article in English | MEDLINE | ID: mdl-21358186

ABSTRACT

Usher syndrome (USH) is a clinically heterogeneous condition characterized by sensorineural hearing loss, progressive retinal degeneration, and vestibular dysfunction. A minimum test battery is described as well as additional clinical evaluations that would provide comprehensive testing of hearing, vestibular function, and visual function in USH patients. USH is also genetically heterogeneous. At least nine genes have been identified with mutations that can cause USH. The proteins encoded by these genes are thought to interact with one another to form a network in the sensory cells of the inner ear and retina.


Subject(s)
Usher Syndromes/genetics , Animals , Disease Models, Animal , Genotype , Humans , Mice , Mutation , Phenotype , Usher Syndromes/diagnosis , Usher Syndromes/physiopathology
11.
Br J Ophthalmol ; 95(4): 574-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21097938

ABSTRACT

AIM: The aim of this study is to assess the role of Frizzled-4 (FZD4) in familial exudative vitreoretinopathy (FEVR) and Coats disease. METHODS: Tissue samples were collected for DNA extraction and automated DNA sequencing of the two coding exons of FZD4 in both directions. Cases carrying a FZD4 mutation and demonstrating extreme disease severity were selected for direct automated sequencing of all coding exons of LRP5, NDP and TSPAN12. Clinical data were obtained for the purpose of identifying genotype-phenotype correlations. RESULTS: 68 probands were diagnosed as having autosomal dominant or sporadic FEVR. Eleven FZD4 mutations (five missense, three deletions, one insertion, two nonsense) were identified. Six of these mutations are novel, and none were found in 346 control chromosomes. In 16 cases of Coats disease, one polymorphism combination was found in two samples: no mutations were detected. No genotype-phenotype correlation emerged. Three severely affected cases with FZD4 mutations failed to show additional mutations in the three other FEVR genes. CONCLUSION: The authors identified 12 FEVR probands with FZD4 mutations. FZD4 mutation screening can be a useful tool especially in mild or atypical cases of FEVR. Germ-line mutations in FZD4 do not appear to be a common cause of Coats disease.


Subject(s)
Eye Diseases, Hereditary/genetics , Frizzled Receptors/genetics , Mutation/genetics , Receptors, G-Protein-Coupled/genetics , Retinal Telangiectasis/genetics , Vitreoretinopathy, Proliferative/genetics , Adolescent , Adult , Aged , Child , Child, Preschool , Exons , Female , Genetic Association Studies , Humans , Male , Middle Aged , Pedigree , Vitreoretinopathy, Proliferative/diagnosis , Young Adult
12.
Am J Med Genet A ; 152A(6): 1474-83, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20503323

ABSTRACT

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable oculocutaneous albinism, immunodeficiency, mild bleeding diathesis, and an accelerated lymphoproliferative state. Abnormal lysosome-related organelle membrane function leads to the accumulation of large intracellular vesicles in several cell types, including granulocytes, melanocytes, and platelets. This report describes a severe case of CHS resulting from paternal heterodisomy of chromosome 1, causing homozygosity for the most distal nonsense mutation (p.E3668X, exon 50) reported to date in the LYST/CHS1 gene. The mutation is located in the WD40 region of the CHS1 protein. The patient's fibroblasts expressed no detectable CHS1. Besides manifesting the classical CHS findings, the patient exhibited hypotonia and global developmental delays, raising concerns about other effects of heterodisomy. An interstitial 747 kb duplication on 6q14.2-6q14.3 was identified in the propositus and paternal samples by comparative genomic hybridization. SNP genotyping revealed no additional whole chromosome or segmental isodisomic regions or other dosage variations near the crossover breakpoints on chromosome 1. Unmasking of a separate autosomal recessive cause of developmental delay, or an additive effect of the paternal heterodisomy, could underlie the severity of the phenotype in this patient.


Subject(s)
Aneuploidy , Chediak-Higashi Syndrome/genetics , Chromosomes, Human, Pair 1/genetics , Chediak-Higashi Syndrome/pathology , Codon, Nonsense , Exons/genetics , Fibroblasts/pathology , Humans , Infant , Lysosomes/pathology , Retina/pathology , Sequence Analysis, DNA
13.
Ophthalmology ; 117(3): 615-22, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20022637

ABSTRACT

PURPOSE: The inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of genetic disorders that share the inability of the bone marrow to produce an adequate number of blood cells. The 4 most frequent syndromes are Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), and Shwachman-Diamond syndrome (SDS). All 4 syndromes have been associated with various physical abnormalities. As part of a genotype/phenotype/cancer susceptibility study, we determined the prevalence of ophthalmic manifestations in these 4 syndromes. DESIGN: Cross-sectional study of a patient cohort. PARTICIPANTS: Seventy-five patients with an IBMFS and 121 of their first-degree relatives were seen in the National Eye Institute, National Institutes of Health, from 2001 to 2007. The patient group included 22 with FA, 28 with DC, 19 with DBA, and 6 with SDS. METHODS: Every participant underwent a complete ophthalmic evaluation and digital facial photography with an adhesive paper ruler on the patient's forehead for an internal measure of scale. Interpupillary distance (IPD), inner canthal distance (ICD), outer canthal distance (OCD), palpebral fissure length (PFL), and corneal diameter (CD) were measured. Thirteen of the 22 patients with FA underwent axial length (AL) measurements by A-scan ultrasonography. MAIN OUTCOME MEASURES: Type and prevalence of ophthalmic manifestations. RESULTS: Ninety-five percent of patients with FA had at least 1 abnormal parameter, and 25% of patients had at least 4 abnormal parameters. Eighty-two percent of patients had small palpebral fissures, 69% of patients had simple microphthalmia, 64% of patients had small OCD, 55% of patients had microcornea, 28% of patients had ptosis, and 6% of patients had epicanthal folds. In patients with DC, abnormalities of the lacrimal drainage system (29%) were the most prevalent findings, followed by retinal abnormalities (pigmentary changes, retinal neovascularization, retinal detachment, exudative retinopathy) in 21%, cicatricial entropion with trichiasis and blepharitis in 7% each, and sparse eyelashes and congenital cataract in 3.5% each. No significant ophthalmic abnormalities were seen in patients with DBA or SDS. CONCLUSIONS: Syndrome-specific ocular findings are associated with FA and DC and may antedate diagnosis of the specific syndrome. Early recognition of these abnormalities is important for optimal management.


Subject(s)
Dyskeratosis Congenita/complications , Eye Abnormalities/etiology , Eye Diseases, Hereditary/etiology , Fanconi Anemia/complications , Orbital Diseases/etiology , Adolescent , Adult , Aged , Anemia, Diamond-Blackfan/complications , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Pedigree , Prevalence , Young Adult
14.
J Pediatr ; 155(3): 386-92.e1, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19540516

ABSTRACT

OBJECTIVES: To describe 3 children with mutations in a Meckel syndrome gene (MKS3), with features of autosomal recessive polycystic kidney disease (ARPKD), nephronophthisis, and Joubert syndrome (JS). STUDY DESIGN: Biochemical evaluations, magnetic resonance and ultrasound imaging, electroretinograms, IQ testing, and sequence analysis of the PKHD1 and MKS3 genes were performed. Functional consequences of the MKS3 mutations were evaluated by cDNA sequencing and transfection studies with constructs of meckelin, the protein product of MKS3. RESULTS: These 3 children with MKS3 mutations had features typical of ARPKD, that is, enlarged, diffusely microcystic kidneys and early-onset severe hypertension. They also exhibited early-onset chronic anemia, a feature of nephronophthisis, and speech and oculomotor apraxia, suggestive of JS. Magnetic resonance imaging of the brain, originally interpreted as normal, revealed midbrain and cerebellar abnormalities in the spectrum of the "molar tooth sign" that characterizes JS. CONCLUSIONS: These findings expand the phenotypes associated with MKS3 mutations. MKS3-related ciliopathies should be considered in patients with an ARPKD-like phenotype, especially in the presence of speech and oculomotor apraxia. In such patients, careful expert evaluation of the brain images can be beneficial because the brain malformations can be subtle.


Subject(s)
Abnormalities, Multiple/genetics , Ciliary Motility Disorders/genetics , Membrane Proteins/genetics , Mutation , Polycystic Kidney, Autosomal Recessive/genetics , Abnormalities, Multiple/diagnosis , Brain/abnormalities , Brain/pathology , Child , Ciliary Motility Disorders/diagnosis , Female , Humans , Kidney/abnormalities , Kidney/diagnostic imaging , Kidney/pathology , Liver/abnormalities , Liver/pathology , Magnetic Resonance Imaging , Male , Polycystic Kidney, Autosomal Recessive/diagnosis , Siblings , Syndrome , Ultrasonography
15.
Lancet ; 373(9679): 1974-86, 2009 Jun 06.
Article in English | MEDLINE | ID: mdl-19476995

ABSTRACT

Neurofibromatosis type 2 is an autosomal-dominant multiple neoplasia syndrome that results from mutations in the NF2 tumour suppressor gene located on chromosome 22q. It has a frequency of one in 25,000 livebirths and nearly 100% penetrance by 60 years of age. Half of patients inherit a germline mutation from an affected parent and the remainder acquire a de novo mutation for neurofibromatosis type 2. Patients develop nervous system tumours (schwannomas, meningiomas, ependymomas, astrocytomas, and neurofibromas), peripheral neuropathy, ophthalmological lesions (cataracts, epiretinal membranes, and retinal hamartomas), and cutaneous lesions (skin tumours). Optimum treatment is multidisciplinary because of the complexities associated with management of the multiple, progressive, and protean lesions associated with the disorder. We review the molecular pathogenesis, genetics, clinical findings, and management strategies for neurofibromatosis type 2.


Subject(s)
Neurofibromatosis 2 , Cataract/etiology , Chromosomes, Human, Pair 22/genetics , Disease Progression , Gene Frequency/genetics , Genes, Neurofibromatosis 2 , Genetic Testing , Humans , Molecular Biology , Mutation/genetics , Nervous System Neoplasms/etiology , Neurofibromatosis 2/diagnosis , Neurofibromatosis 2/epidemiology , Neurofibromatosis 2/genetics , Neurofibromatosis 2/therapy , Neurofibromin 2/genetics , Patient Care Team/organization & administration , Pedigree , Penetrance , Peripheral Nervous System Diseases/etiology , Skin Neoplasms/etiology , Survival Rate
16.
Pediatr Blood Cancer ; 53(3): 520-3, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19415736

ABSTRACT

Dyskeratosis congenita (DC) is a heterogeneous inherited bone marrow failure syndrome, characterized by abnormally short telomeres and mutations in telomere biology genes. The spectrum of telomere biology disorders is growing and the clinical management of these patients is complex. A DC-specific workshop was held at the NIH on September 19, 2008; participants included physicians, patients with DC, their family members, and representatives from other support groups. Data from the UK's DC Registry and the NCI's DC cohort were described. Updates on the function of the known DC genes were presented. Clinical aspects discussed included androgen therapy, stem cell transplant, cancer risk, and cancer screening. Families with DC met for the first time and formed a family support group (http://www.dcoutreach.com/). Ongoing, open collaboration between the clinical, scientific, and family communities is required for continued improvement in our understanding of DC and the clinical consequences of telomeric defects.


Subject(s)
Dyskeratosis Congenita/therapy , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Humans , Telomere
17.
Mol Genet Metab ; 97(3): 227-33, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19398212

ABSTRACT

Hermansky-Pudlak syndrome (HPS) develops from defects in the biogenesis and/or function of lysosome-related organelles essential to membrane and protein trafficking. Of the eight known human subtypes, only HPS-1 and HPS-4 develop pulmonary fibrosis in addition to the general clinical manifestations of oculocutaneous albinism and bleeding diathesis. We identified HPS-1 in three unrelated patients from different regions of India, who presented with iris transillumination, pale fundi, hypopigmentation, nystagmus, decreased visual acuity, and a bleeding diathesis. Two of these patients carried the homozygous mutation c.398+5G>A (IVS5+5G>A) in HPS1, resulting in skipping of exon 5 in HPS1 mRNA. The third patient carried a novel homozygous c.988-1G>T mutation that resulted in in-frame skipping of HPS1 exon 12 and removes 56 amino acids from the HPS1 protein. Given the discovery of HPS-1 in an ethnic group where oculocutaneous albinism (OCA) is highly prevalent, it is possible that HPS in India is under-diagnosed. We recommend that unconfirmed OCA patients in this ethic group be considered for mutational screening of known HPS genes, in particular c.398+5G>A and c.980-1G>T, to ensure that patients can be monitored and treated for clinical complications unique to HPS.


Subject(s)
Asian People/genetics , Hermanski-Pudlak Syndrome/genetics , Base Sequence , Blood Platelets/ultrastructure , Child , Child, Preschool , DNA Mutational Analysis , Female , Humans , India , Infant , Male , Membrane Proteins/genetics , Molecular Sequence Data
18.
Hum Mutat ; 29(4): 502-11, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18181211

ABSTRACT

Recessive mutations of MYO7A, encoding unconventional myosin VIIA, can cause either a deaf-blindness syndrome (type 1 Usher syndrome; USH1B) or nonsyndromic deafness (DFNB2). In our study, deafness segregating as a recessive trait in 24 consanguineous families showed linkage to markers for the DFNB2/USH1B locus on chromosome 11q13.5. A total of 23 of these families segregate USH1 due to 17 homozygous mutant MYO7A alleles, of which 14 are novel. One family segregated nonsyndromic hearing loss DFNB2 due to a novel three-nucleotide deletion in an exon of MYO7A (p.E1716del) encoding a region of the tail domain. We hypothesized that DFNB2 alleles of MYO7A have residual myosin VIIA. To address this question we investigated the effects of several mutant alleles by making green fluorescent protein (GFP) tagged cDNA expression constructs containing engineered mutations of mouse Myo7a at codons equivalent to pathogenic USH1B and DFNB2 alleles of human MYO7A. We show that in transfected mouse hair cells an USH1B mutant GFP-myosin VIIa does not localize properly to inner ear hair cell stereocilia. However, a GFP-myosin VIIa protein engineered to have an equivalent DFNB2 mutation to p.E1716del localizes correctly in transfected mouse hair cells. This finding is consistent with the hypothesis that p.E1716del causes a less severe phenotype (DFNB2) than the USH1B-associated alleles because the resulting protein retains some degree of normal function.


Subject(s)
Deafness/genetics , Dyneins/genetics , Mutation , Myosins/genetics , Adult , Alleles , Amino Acid Sequence , Animals , Base Composition , Chromosomes, Human, Pair 11/genetics , Consanguinity , DNA, Complementary/genetics , Deafness/metabolism , Deafness/physiopathology , Dyneins/chemistry , Dyneins/metabolism , Exons , Female , Genes, Recessive , Genetic Linkage , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Hair Cells, Auditory, Inner/metabolism , Humans , Kinetics , Male , Mice , Middle Aged , Models, Molecular , Molecular Sequence Data , Myosin VIIa , Myosins/chemistry , Myosins/metabolism , Pedigree , Phenotype , Protein Conformation , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Deletion , Sequence Homology, Amino Acid , Transfection , Usher Syndromes/genetics , Usher Syndromes/metabolism , Usher Syndromes/physiopathology
19.
Surv Ophthalmol ; 52(1): 97-105, 2007.
Article in English | MEDLINE | ID: mdl-17212992

ABSTRACT

Cystinosis is a rare autosomal recessive metabolic disorder characterized by the intracellular accumulation of cystine, the disulfide of the amino acid cysteine, in many organs and tissues. Infantile nephropathic cystinosis is the most severe phenotype. Corneal crystal accumulation and pigmentary retinopathy were originally the most commonly described ophthalmic manifestations, but successful kidney transplantation significantly changed the natural history of the disease. As cystinosis patients now live longer, long-term complications in extrarenal tissues, including the eye, have become apparent. A case of an adult patient with infantile nephropathic cystinosis is reported. He presented with many long-term ocular complications of cystinosis. After 4 years of follow-up, the patient died from sepsis. Pathology of the phthisical eyes demonstrated numerous electron-transparent polygonal spaces, bounded by single membrane, in corneal cells, retinal pigment epithelial cells, and even choroidal endothelial cells. The ophthalmic manifestations and pathology of infantile nephropathic cystinosis are discussed and reviewed in light of the current report and other cases in the literature.


Subject(s)
Choroid Diseases/pathology , Corneal Diseases/pathology , Cystinosis/pathology , Kidney Diseases/pathology , Retinal Diseases/pathology , Adult , Choroid Diseases/metabolism , Corneal Diseases/metabolism , Cysteine/metabolism , Cystinosis/metabolism , Fatal Outcome , Humans , Kidney Diseases/metabolism , Male , Retinal Diseases/metabolism
20.
Retin Cases Brief Rep ; 1(4): 232-5, 2007.
Article in English | MEDLINE | ID: mdl-25390987

ABSTRACT

PURPOSE: To report variations in the inheritance pattern and clinical presentation of crystalline retinopathies. METHODS: Two different families with crystalline retinopathy were studied with a complete family history and ophthalmologic examination including Goldmann kinetic perimetry and electroretinography. Genetic studies were performed in one of the families. RESULTS: One of the families had a clearly autosomal dominant mode of inheritance while the other family most likely follows an autosomal recessive pattern. Several members in each family had significant retinal pigment epithelial atrophy, intraretinal crystals, relatively pink optic nerves, and paracentral visual field defects, all of which are clinical features resembling those of Bietti crystalline retinopathy. Examination of peripheral leukocytes using transmission electron microscopy in selected affected members showed no evidence of classical lysosomal crystals that are characteristics for Bietti crystalline retinopathy. No pathogenic mutations were identified in the CYP4V2 gene. CONCLUSIONS: Not all crystalline retinopathies are Bietti's. Further genetic, biochemical, and pathologic studies are required to better differentiate between these retinopathies.

SELECTION OF CITATIONS
SEARCH DETAIL
...